Trends and patterns of neurotology drug prescriptions on a nationwide insurance database

Goshtasbi, Khodayar; Abouzari, Mehdi; Abiri, Arash; Ziai, Kasra; Lehrich, Brandon M.; Risbud, Adwight; Bayginejad, Soha; Lin, Harrison W.; Djalilian, Hamid R.

doi:10.1002/lio2.617

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sodium salt of MTK has been available since 1995 as Singulair ® (Merck Sharp & Dohme, Kenilworth, NJ, USA) and has been increasingly prescribed in recent years [119]. However, MTK metabolism is still poorly understood.…”

Section: Montelukast Metabolism and Bioavailabilitymentioning

confidence: 99%

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Marques

Justino

2022

Pharmaceuticals

View full text Add to dashboard Cite

Increasing environmental distress is associated with a growing asthma incidence; no treatments are available but montelukast (MTK)—an antagonist of the cysteinyl leukotrienes receptor 1—is widely used in the management of symptoms among adults and children. Recently, new molecular targets have been identified and MTK has been proposed for repurposing in other therapeutic applications, with several ongoing clinical trials. The proposed applications include neuroinflammation control, which could be explored in some neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (AD and PD). However, this drug has been associated with an increasing number of reported neuropsychiatric adverse drug reactions (ADRs). Besides, and despite being on the market since 1998, MTK metabolism is still poorly understood and the mechanisms underlying neuropsychiatric ADRs remain unknown. We review the role of MTK as a modulator of leukotriene pathways and systematize the current knowledge about MTK metabolism. Known toxic effects of MTK are discussed, and repurposing applications are presented comprehensively, with a focus on AD and PD.

show abstract

Section: Montelukast Metabolism and Bioavailabilitymentioning

confidence: 99%

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Marques

Justino

2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The sodium salt of MTK has been available since 1995 as Singulair® (Merck Sharp & Dohme), and has been increasingly prescribed in recent years [114]. However, MTK metabolism is still poorly understood.…”

Section: Montelukast Metabolism and Bioavailabilitymentioning

confidence: 99%

Leukotrienes vs. Montelukast – Activity, Metabolism, and Toxicity Hints for Repurposing

Marques¹,

Marques²,

Justino³

2022

Preprint

View full text Add to dashboard Cite

Increasing environmental distress is associated with a growing asthma incidence and, with no treatments available, montelukast (MTK) – an antagonist of the cysteinyl leukotrienes receptor 1 – is widely used in the management of symptoms among adults and children. Recently, new molecular targets have been identified and MTK has been proposed for repurposing in other therapeutic applications, with several ongoing clinical trials. The proposed applications include neuroinflammation control, which could be explored in some neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (AD and PD). However, this drug has been associated with an increasing number of reported neuropsychiatric adverse drug reactions. Besides, and despite being on the market since 1998, MTK metabolism is still poorly understood and the mechanisms underlying neuropsychiatric ADRs remain unknown. We review the role of MTK as modulator of leukotriene pathways and systematize the knowledge about MTK metabolism. Known toxic effects of MTK are discussed, and repurposing applications are presented comprehensively, with a focus on AD and PD.

show abstract

The rising cost of rhinologic medications

Vasudev¹,

Torabi²,

Michelle³

et al. 2023

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Trends and patterns of neurotology drug prescriptions on a nationwide insurance database

Cited by 3 publications

References 21 publications

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing

Leukotrienes vs. Montelukast – Activity, Metabolism, and Toxicity Hints for Repurposing

The rising cost of rhinologic medications

Contact Info

Product

Resources

About